Patient-specific enhancers in genetically uniform leukemias

The short course of talquetamab treatment used in this study may represent an opportunity of re-treatment with anti-GPRC5D immunotherapies in case of relapse after anti-BCMA CAR-T.Indeed, GPRC5D loss is described in most patients progressing while on talquetamab continuous treatment, 7 but it may be less frequent with fixed-duration, short-course therapy.In conclusion, data from this real-life experience may be the proof of concept of a sequential BsAb-CAR-T approach.GPRC5D CAR-Ts are currently in clinical development, 9 and a bridging therapy with anti-BCMA BsAbs may be an effective therapy in this context as well, warranting further investigation.